Deciphera Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 61 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-12-23: Reporting owner Kelly Thomas Patrick; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-12-12: Reporting owner Morl Christopher John; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-12-10: Reporting owner Morl Christopher John; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-12-10: Reporting owner Flynn Daniel Lee; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-12-23 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 83,008 owned after | $1.89 exercise price | 2019-12-26 | |
| 2019-12-12 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,034 195,446 owned after | $3.95 exercise price | 2019-12-13 | |
| 2019-12-10 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,647 210,480 owned after | $3.95 exercise price | 2019-12-11 | |
| 2019-12-10 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −28,822 107,827 owned after | $1.89 exercise price | 2019-12-11 | |
| 2019-12-10 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −93,930 13,897 owned after | $1.89 exercise price | 2019-12-11 | |
| 2019-12-09 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,387 222,127 owned after | $3.95 exercise price | 2019-12-11 | |
| 2019-12-09 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −30,175 136,649 owned after | $1.89 exercise price | 2019-12-11 | |
| 2019-12-04 | Squarer Ron Director | 4/A | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,900 21,900 owned after | $51.85 exercise price | 2020-02-20 | |
| 2019-12-04 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,000 24,000 owned after | $51.85 exercise price | 2019-12-06 | |
| 2019-12-03 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,034 225,514 owned after | $3.95 exercise price | 2019-12-05 | |
| 2019-11-25 | Friedman Franklin Stuart Director | 4/A | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,400 23,400 owned after | $48.44 exercise price | 2020-02-20 | |
| 2019-11-25 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,000 24,000 owned after | $48.44 exercise price | 2019-11-26 | |
| 2019-11-11 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −143,185 166,824 owned after | $1.89 exercise price | 2019-11-13 | |
| 2019-11-08 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,742 310,009 owned after | $1.89 exercise price | 2019-11-13 | |
| 2019-11-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 479,635 owned after | $1.89 exercise price | 2019-11-05 | |
| 2019-11-01 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 63,408 owned after | $1.89 exercise price | 2019-11-05 | |
| 2019-10-28 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −29,820 319,751 owned after | $1.89 exercise price | 2019-10-30 | |
| 2019-10-28 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,750 123,008 owned after | $1.89 exercise price | 2019-10-30 | |
| 2019-10-15 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $34.43 exercise price | 2019-10-17 | |
| 2019-09-11 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,250 126,758 owned after | $1.89 exercise price | 2019-09-13 | |
| 2019-09-11 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,500 487,135 owned after | $1.89 exercise price | 2019-09-13 | |
| 2019-09-03 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 509,635 owned after | $1.89 exercise price | 2019-09-05 | |
| 2019-08-13 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,500 517,135 owned after | $1.89 exercise price | 2019-08-13 | |
| 2019-08-13 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,250 138,008 owned after | $1.89 exercise price | 2019-08-13 | |
| 2019-08-13 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −123,107 349,571 owned after | $1.89 exercise price | 2019-08-13 | |
| 2019-08-13 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 88,408 owned after | $1.89 exercise price | 2019-08-13 | |
| 2019-07-08 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,000 24,000 owned after | $22.49 exercise price | 2019-07-08 | |
| 2019-06-19 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −177 149,258 owned after | $1.89 exercise price | 2019-06-21 | |
| 2019-06-11 | Ross Michael Jay Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $21.05 exercise price | 2019-06-13 | |
| 2019-06-11 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $21.05 exercise price | 2019-06-13 | |
| 2019-06-11 | Martin John Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $21.05 exercise price | 2019-06-13 | |
| 2019-06-11 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $21.05 exercise price | 2019-06-13 | |
| 2019-06-11 | Benz Edward J. JR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $21.05 exercise price | 2019-06-13 | |
| 2019-06-11 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $21.05 exercise price | 2019-06-13 | |
| 2019-06-03 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,100 149,435 owned after | $1.89 exercise price | 2019-06-05 | |
| 2019-05-22 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −100 151,535 owned after | $1.89 exercise price | 2019-05-23 | |
| 2019-05-21 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,373 151,635 owned after | $1.89 exercise price | 2019-05-23 | |
| 2019-05-01 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,500 153,008 owned after | $1.89 exercise price | 2019-05-03 | |
| 2019-03-18 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −2,250 397,750 owned after | $25.40 exercise price | 2020-03-20 | |
| 2019-03-18 | Hoerter Steven L. Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +400,000 400,000 owned after | $25.40 exercise price | 2019-03-20 | |
| 2019-02-21 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −24,500 15,050 owned after | $3.95 exercise price | 2019-02-25 | |
| 2019-02-19 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 166,508 owned after | $1.89 exercise price | 2019-02-20 | |
| 2019-02-19 | Taylor Michael Douglas Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,997 539,635 owned after | $1.89 exercise price | 2019-02-19 | |
| 2019-02-15 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,782 113,408 owned after | $1.89 exercise price | 2019-02-19 | |
| 2019-02-15 | Taylor Michael Douglas Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,934 543,632 owned after | $1.89 exercise price | 2019-02-19 | |
| 2019-02-14 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,101 131,190 owned after | $1.89 exercise price | 2019-02-19 | |
| 2019-02-14 | Taylor Michael Douglas Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −500 548,566 owned after | $1.89 exercise price | 2019-02-19 | |
| 2019-02-13 | Taylor Michael Douglas Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,666 549,066 owned after | $1.89 exercise price | 2019-02-14 | |
| 2019-02-13 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,922 132,291 owned after | $1.89 exercise price | 2019-02-14 | |
| 2019-02-12 | Taylor Michael Douglas Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −200 551,732 owned after | $1.89 exercise price | 2019-02-14 | |
| 2019-02-12 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −600 135,213 owned after | $1.89 exercise price | 2019-02-14 | |
| 2019-02-05 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,595 135,813 owned after | $1.89 exercise price | 2019-02-07 | |
| 2019-02-05 | Taylor Michael Douglas Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,700 551,932 owned after | $1.89 exercise price | 2019-02-07 | |
| 2019-01-30 | Taylor Michael Douglas Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +263,000 263,000 owned after | $26.35 exercise price | 2019-02-01 | |
| 2019-01-30 | Ruddy Stephen B. Officer (Chief Technical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,000 52,000 owned after | $26.35 exercise price | 2019-02-01 | |
| 2019-01-30 | Martin Daniel C. Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,000 52,000 owned after | $26.35 exercise price | 2019-02-01 | |
| 2019-01-30 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $26.35 exercise price | 2019-02-01 | |
| 2019-01-30 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $26.35 exercise price | 2019-02-01 | |
| 2019-01-16 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −152,629 472,678 owned after | $1.89 exercise price | 2019-01-18 | |
| 2019-01-11 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −300 625,307 owned after | $1.89 exercise price | 2019-01-15 | |
| 2019-01-07 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 168,008 owned after | $1.89 exercise price | 2019-01-09 |